Drug Type AAV based gene therapy |
Synonyms rAAV Anc80 KCNQ4, rAAV Anc80KCNQ4 |
Target |
Action modulators |
Mechanism Kv7.4 modulators(potassium voltage-gated channel subfamily Q member 4 modulators) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhaseDiscovery |
First Approval Date- |
Regulation- |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Hearing Loss | Discovery | United States | 12 May 2021 |





